-
1Academic Journal
Authors: K. A. Turupaev, A. V. Klimov, O. A. Khalmurzaev, G. A. Arakelyan, D. D. Ladyko, S. D. Bezhanova, V. O. Vorob’eva, A. V. Smirnova, V. B. Matveev, К. А. Турупаев, А. В. Климов, О. А. Халмурзаев, Г. А. Аракелян, Д. Д. Ладыко, С. Д. Бежанова, В. О. Воробьева, А. В. Смирнова, В. Б. Матвеев
Source: Cancer Urology; Том 19, № 4 (2023); 119-124 ; Онкоурология; Том 19, № 4 (2023); 119-124 ; 1996-1812 ; 1726-9776
Subject Terms: светлоклеточный почечно-клеточный рак, organ-preserving surgical treatment, tumor thrombus, synchronous bilateral kidney cancer, papillary renal cell carcinoma, clear-cell renal cell carcinoma, органосохраняющее хирургическое лечение, опухолевый венозный тромбоз, синхронный двусторонний рак почек, папиллярный почечно-клеточный рак
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1688/1499; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1323; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1324; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1325; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1326; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1327; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1328; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1329; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1688/1330; Globocan (IARC) 2020. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf.; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Zhang C., Li X., Hao H. et al. The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases. BJU Int 2012; 110(11 Pt B):E481–5. DOI:10.1111/j.1464-410X.2012.11173.x; Van Poppel H., Da Pozzo L., Albrecht W. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59(4):543–52. DOI:10.1016/j.eururo.2010.12.013; Scosyrev E., Messing E.M., Sylvester R. et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014;65(2):372–7. DOI:10.1016/j.eururo.2013.06.044; Fergany A.F., Hafez K.S., Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000;163(2):442–5.; Patel S.H., Uzzo R.G., Larcher A. et al. Oncologic and functional outcomes of radical and partial nephrectomy in pt3a pathologically upstaged renal cell carcinoma: a multi-institutional analysis. Clin Ge-nitourin Cancer 2020;18(6):e723–9. DOI:10.1016/j.clgc.2020.05.002; Kolla S.B., Ercole C., Spiess P.E. et al. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int 2010;106(10):1494–8. DOI:10.1111/j.1464-410X.2010.09293.x; Yim K., Aron M., Rha K.H. et al. Outcomes of robot-assisted partial nephrectomy for clinical T3a renal masses: a multicenter analysis. Eur Urol Focus 2021;7(5):1107–14. DOI:10.1016/j.euf.2020.10.011; Woldu S.L., Barlow L.J., Patel T. et al. Single institutional experience with nephron-sparing surgery for pathologic stage T3bNxM0 renal cell carcinoma confined to the renal vein. Urology 2010;76(3):639–42. DOI:10.1016/j.urology.2009.10.073; Marra G., Gontero P., Brattoli M. et al. Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort. Urol Oncol 2018;36(7):339.e1–8. DOI:10.1016/j.urolonc.2018.04.007; Morgan T.N., Dai J.C., Kusin S. et al. Clinical outcomes of robotic assisted partial nephrectomy for pathologic T3a renal masses with venous tumor thrombus. Urology 2022;159:120–6. DOI:10.1016/j.urology.2021.06.054; Zisman A., Pantuck A.J., Wieder J. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20(23):4559–66. DOI:10.1200/JCO.2002.05.111; Leibovich B.C., Blute M.L., Cheville J.C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97(7):1663–71. DOI:10.1002/cncr.11234; Eisen T., Frangou E., Oza B. et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol 2020;38:4064–75. DOI:10.1200/JCO.20.01800; Gross-Goupil M., Kwon T., Eto M. et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018;29(12):2371–8. DOI:10.1093/annonc/mdy454; Haas N.B., Manola J., Uzzo R.G. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387(10032):2008–16. DOI:10.1016/S0140-6736(16)00559-6; Motzer R.J., Haas N.B., Donskov F. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35(35):3916–23. DOI:10.1200/JCO.2017.73.5324; Staehler M., Motzer R.J., George D.J. et al. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol 2018;29(10):2098–104. DOI:10.1093/annonc/mdy329; Powles T., Tomczak P., Park S.H. et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23(9):1133–44. DOI:10.1016/S1470-2045(22)00487-9; https://oncourology.abvpress.ru/oncur/article/view/1688
-
2Academic Journal
Authors: E. V. Grebenkin, A. M. Pshikhachev, B. E. Osmolovskiy, A. A. Epishkina, E. Yu. Kozhevnikova, N. I. Sorokin, A. A. Kamalov, Е. В. Гребенкин, А. М. Пшихачев, Б. Е. Осмоловский, А. А. Епишкина, Е. Ю. Кожевникова, Н. И. Сорокин, А. А. Камалов
Source: Cancer Urology; Том 19, № 3 (2023); 119-125 ; Онкоурология; Том 19, № 3 (2023); 119-125 ; 1996-1812 ; 1726-9776
Subject Terms: мутация BRAF, nephroblastoma, Wilms’ tumor, papillary renal cell carcinoma, BRAF mutation, нефробластома, опухоль Вильмса, папиллярный почечно-клеточный рак
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1696/1485; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1696/1331; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1696/1332; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1696/1333; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1696/1334; Pages A., Granier M. Nephrogenic nephroma. Arch Anat Cytol Pathol 1980;28(2):99-103.; Bastide C., Rambeaud J.J., Bach A.M., Russo P. Metanephric adenoma of the kidney: clinical and radiological study of nine cases. BJU Int 2009;103:1544-8. DOI:10.1111/j.1464-410X.2009.08357.x; Paner G.P., Turk T.M., Clark J.I. et al. Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodes. Arch Pathol Lab Med 2005;129(10):1317-21. DOI:10.5858/2005-129-1317-PSIMAA; Renshaw A.A., Freyer D.R., Hammers Y.A. Metastatic metanephric adenoma in a child. Am J Surg Pathol 2000;24(4):570-4. DOI:10.1097/00000478-200004000-00012; Drut R., Drut R.M., Ortolani C. Metastatic metanephric adenoma with foci of papillary carcinoma in a child: a combined histologic, immunohistochemical, and FISH study. Int J Surg Pathol 2001;9(3):241-7. DOI:10.1177/106689690100900313; Choueiri T.K., Cheville J., Palescandolo E. et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol 2012;62(5):917-22. DOI:10.1016/j.eururo.2012.05.051; Udager A.M., Pan J., Magers M.J. et al. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. Am J Surg Pathol 2015;39(4):549-57. DOI:10.1097/PAS.0000000000000377; Kinney S.N., Eble J.N., Hes O. et al. Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. Mod Pathol 2015;28(9):1236-48. DOI:10.1038/modpathol.2015.81; Wobker S.E., Matoso A., Pratilas C.A. et al. Metanephric adenoma-epithelial wilms tumor overlap lesions: an analysis of BRAF status. Am J Surg Pathol 2019;43(9):1157-69. DOI:10.1097/PAS.0000000000001240; Muir T.E., Cheville J.C., Lager D.J. Metanephric adenoma, nephrogenic rests, and Wilms' tumor: a histologic and immunophenotypic comparison. Am J Surg Pathol 2001;25(10):1290-6. DOI:10.1097/00000478-200110000-00010; Wang P., Tian Y., Xiao Y. et al. A metanephric adenoma of the kidney associated with polycythemia: a case report. Oncol Lett 2016;11(1): 352-4. DOI:10.3892/ol.2015.3868; Jiang T., Li W., Lin D. et al. Imaging features of metanephric adenoma and their pathological correlation. Clin Radiol 2019;74(5): 408.e9-17. DOI:10.1016/j.crad.2019.01.013; Zhu D., Zhu L., Wu J. et al. Metanephric adenoma: association between the imaging features of contrast-enhanced ultrasound and clinicopathological characteristics. Gland Surg 2021;10(8):2490-9. DOI:10.21037/gs-21-437; Torricelli F.C., Marchini G.S., Campos R.S. et al. Metanephric adenoma: clinical, imaging, and histological findings. Clinics (Sao Paulo) 2011;66(2):359-61. DOI:10.1590/S1807-59322011000200030; Li G., Fu F., Song H. et al. Computed tomography imaging spectrum and the histopathological features of adult metanephric adenoma. Br J Radiol 2015;88(1051):20140807. DOI:10.1259/bjr.20140807; Delzongle M., Boukamel S., Kemeny F. et al. Metanephric adenoma: MR imaging features with histopathological correlation. Diagn Interv Imaging 2015;96(4):387-90. DOI:10.1016/j.diii.2014.11.005; Yan J., Cheng J.L., Li C.F. et al. The findings of CT and MRI in patients with metanephric adenoma. Diagn Pathol 2016;11(1):104. DOI:10.1186/s13000-016-0535-x; WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. In: WHO Classification of Tumours Series. 5th edn. Vol. 8. Lyon (France): International Agency for Research on Cancer, 2022. Available at: https://publications.iarc.fr/610.; Kastan R., Zizlavska M. Metanephric adenoma. A case report and literature review. Cesk Patol 2019;55(3):165-9.; Zhang W., Song Y., Cui H., Zhang Y. Metanephric adenoma of the kidney: a case report and literature review. Asian J Surg 2023;46(6):2319-20. DOI:10.1016/j.asjsur.2022.12.030; Saremian J., Kubik M.J., Masood S. Cytologic features of metanephric adenoma of the kidney: case report and review of the literature. Lab Med 2015;46(2):153-8. DOI:10.1309/LMW2MHDM6EILGQH2; Rodriguez-Zarco E., Machuca-Aguado J., Madas-Garda L. et al. Metanephric adenoma: molecular study and review of the literature. Oncotarget 2022;13:387-92. DOI:10.18632/oncotarget.28192; Brown J.A., Anderl K.L., Borell T.J. et al. Simultaneous chromosome 7 and 17 gain and sex chromosome loss provide evidence that renal metanephric adenoma is related to papillary renal cell carcinoma. J Urol 1997;158(2):370-4. DOI:10.1016/S0022-5347(01)64482-3; Cossu-Rocca P., Eble J.N., Delahunt B. et al. Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol 2006;19(4):488-93. DOI:10.1038/modpathol.3800565; Calio A., Eble J.N., Hes O. et al. Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. Oncotarget 2016;8(33):54096-105. DOI:10.18632/oncotarget.11117; Ding Y., Wang C., Li X. et al. Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases. Diagn Pathol 2018;13(1):54. DOI:10.1186/s13000-018-0732-x; Catic A., Kurtovic-Kozaric A., Sophian A. et al. KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas. BMC Med Genet 2020;21(1):202. DOI:10.1186/s12881-020-01143-6; Chan E., Stohr B.A., Croom N.A. et al. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution. Histopathology 2020;76(7):1084-90. DOI:10.1111/his.14094; Lenci N., Francesco P., Scarciglia E. et al. Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process. Med Mol Morphol 2021;54(2):187-91. DOI:10.1007/s00795-020-00269-z; Li G., Tang Y., Zhang R. et al. Adult metanephric adenoma presumed to be all benign? A clinical perspective. BMC Cancer 2015;15:310. DOI:10.1186/s12885-015-1211-3; https://oncourology.abvpress.ru/oncur/article/view/1696